Back to Cell Types

SW1710Homo sapiens (Human)Cancer cell line

Also known as: SW 1710, SW-1710

🤖 AI SummaryBased on 12 publications

Quick Overview

Bladder cancer cell line with genetic mutations and potential for research applications.

Detailed Summary

SW1710 is a bladder cancer cell line derived from a human tumor, characterized by specific genetic mutations that make it a valuable tool for studying bladder cancer biology and therapeutic responses. This cell line has been extensively analyzed for mutations in key genes such as TERT, PIK3CA, and others, which are associated with cancer progression and drug sensitivity. The presence of these mutations allows researchers to investigate the molecular mechanisms underlying bladder cancer and to develop targeted therapies. SW1710 is also used in studies involving the assessment of drug responses and the identification of potential biomarkers for early detection and treatment monitoring.

Research Applications

Genetic mutation analysisDrug sensitivity testingBiomarker discoveryMolecular mechanism studies

Key Characteristics

Mutations in TERT promoterMutations in PIK3CAHomozygous deletions in CDKN2AExpression of specific oncogenes

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1721
Species	Homo sapiens (Human)

Donor Information

Age	84
Age Category	Adult
Sex	Female
Race	caucasian

Disease Information

Disease	Bladder carcinoma
Lineage	Bladder/Urinary Tract
Subtype	Bladder Urothelial Carcinoma
OncoTree Code	BLCA

DepMap Information

Source Type	DSMZ
Source ID	ACH-000566_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg273Cys (c.817C>T)	Homozygous	-	PubMed=35933914
MutationSimple	TERT	c.1-124C>T (c.228C>T) (C228T)	Unspecified	In promoter	from parent cell line Hep-G2

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

11,12

D10S1248

12,17

D12S391

20,22

D13S317

12

D16S539

8,11

D18S51

15,17

D19S433

14,15

D1S1656

15

D21S11

28,30

D22S1045

15,16

D2S1338

19,20

D2S441

10,11

D3S1358

16

D5S818

12

D7S820

8,11

D8S1179

9,12

FGA

25

Penta D

9,11

Penta E

7,14

TH01

7,8,9.3

TPOX

9,11

vWA

16,17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Systematic review: characteristics and preclinical uses of bladder cancer cell lines.

Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.

Bladder Cancer 4:169-183(2018).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.

Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.

Oncogene 36:35-46(2017).

Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Chanock S.J., Valencia A., Real F.X.

BMC Genomics 16:1019.1-1019.2(2015).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Chanock S.J., Valencia A., Real F.X.

BMC Genomics 16:403.1-403.16(2015).

Identification of mutations in distinct regions of p85 alpha in urothelial cancer.

Knowles M.A.

PLoS ONE 8:E84411-E84411(2013).

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Hurst C.D., Platt F.M., Knowles M.A.

Eur. Urol. 65:367-369(2014).

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.

Eur. Urol. 65:360-366(2014).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

Carrato A., Tardon A., Serra C., Real F.X.

Cancer Res. 66:7401-7404(2006).

Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.

Knowles M.A.

Genes Chromosomes Cancer 43:315-328(2005).

Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines.

Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.

Genes Chromosomes Cancer 34:86-96(2002).

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

Wright W.C., Daniels W.P., Fogh J.

J. Natl. Cancer Inst. 66:239-247(1981).

Morphological, biological, and biochemical characteristics of human bladder transitional cell carcinomas grown in tissue culture and in nude mice.

Kyriazis A.A., Kyriazis A.P., McCombs W.B. 3rd, Peterson W.D. Jr.

Cancer Res. 44:3997-4005(1984).

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

Web Resources